Juno Therapeutics To Present Updated Data

Juno Therapeutics said it will present updates on its investigational products JCAR017 and JCAR014, currently being developed to target CD19, a protein expressed on the surface of almost all B cell malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia and acute lymphoblastic leukemia.

New data from the ongoing phase 1 trial evaluating JCAR017 in adult patients with relapsed or refractory aggressive non-Hodgkin lymphoma -diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, follicular lymphoma Grade 3B, and mantle cell lymphoma will be presented, with increased patient numbers and longer duration of follow-up reported at two dose levels as compared to previous presentations.

Updated safety data will also be presented from the ongoing phase 1 trial evaluating JCAR014 in adult patients with relapsed or refractory acute lymphoblastic leukemia non-Hodgkin lymphoma, or chronic lymphocytic leukemia

Leave a Comment